Related Experiment Videos

Treatment of Gram-negative bacillary meningitis with intrathecal gentamicin

Insights

Intrathecal gentamicin effectively treats gram-negative bacillary meningitis, achieving sterile cerebrospinal fluid in 95% of cases. This antibiotic administration method demonstrated a 77% survival rate with no observed toxic side effects in patients.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Neurology

Background:

  • Gram-negative bacillary meningitis poses a significant threat, often requiring intensive treatment.
  • Intrathecal antibiotic delivery is explored for direct central nervous system infection management.

Purpose of the Study:

  • To evaluate the efficacy and safety of intrathecal gentamicin for treating gram-negative bacillary meningitis.
  • To assess gentamicin concentrations in cerebrospinal fluid following intralumbar and intraventricular administration.

Main Methods:

  • Twenty-eight patients with gram-negative bacillary meningitis received intralumbar or intraventricular gentamicin combined with systemic antibiotics.
  • Cerebrospinal fluid (CSF) gentamicin levels were measured 24 hours post-administration.
  • Treatment outcomes, including CSF sterility and patient survival, were recorded.

Main Results:

  • Sterile CSF was achieved in 95% of documented gram-negative bacillary meningitis episodes with >1 day of therapy.
  • Seventy-seven percent of treated patients survived their infection.
  • Mean CSF gentamicin levels were 5.9 ug/ml (intralumbar) and 11.1 ug/ml (intraventricular).

Conclusions:

  • Intrathecal gentamicin, via intralumbar or intraventricular routes, is safe and effective for gram-negative bacillary meningitis.
  • This administration method aids in achieving CSF sterility and improving patient survival rates.
  • No toxic side effects were observed from intrathecal gentamicin administration.

Related Concept Videos